Compare Adaptive Biotechnologies Corp (ADPT) vs Brunswick Corporation (BC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Brunswick Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Brunswick Corporation trades at $75.63 (market cap $5.02B). The key difference: Brunswick Corporation is the larger of the two by market cap, and Brunswick Corporation pays a 2.28% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BC | |
|---|---|---|
Market Cap | $3.33B | $5.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $89.22 |
52-Week Low | $10.24 | $56.64 |
Enterprise Value | $3.19B | $7.19B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BC trades at $77.33, down 2.23% today, with a bearish technical signal and mixed earnings history. Revenue declined to $5.36B in 2025 with a net loss of $137.30M, though recent quarters beat expectations. The company maintains strong analyst support with a $86.40 consensus target and announced a $0.44 dividend for H1-26. Cash flow improved to a near-neutral -$11M in 2025 from deeper losses in prior years.
Outlook is cautious due to profitability challenges and high P/E of 73.92, but expansion news like Freedom Boat Club's 450th location offers growth potential. Risks include sustained negative margins and debt levels, while institutional buy ratings suggest confidence in a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →
